METHOD FOR GENERATING IMMUNE CELLS RESISTANT TO ARGININE AND/OR TRYPTOPHAN DEPLETED MICROENVIRONMENT

(19)

(11)

EP 3 129 473 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	23.12.2020 Bulletin 2020/52

(45)	Mention of the grant of the patent:
	18.03.2020 Bulletin 2020/12

(21)	Application number: 15715273.7

(22)	Date of filing: 10.04.2015

(51)

International Patent Classification (IPC):

C12N 5/10^(2006.01)
A61K 35/14^(2015.01)

A61K 35/12^(2015.01)

(86)	International application number:
	PCT/EP2015/057865

(87)	International publication number:
	WO 2015/155341 (15.10.2015 Gazette 2015/41)

(54)

METHOD FOR GENERATING IMMUNE CELLS RESISTANT TO ARGININE AND/OR TRYPTOPHAN DEPLETED MICROENVIRONMENT

VERFAHREN ZUR ERZEUGUNG VON IMMUNZELLEN, DIE GEGEN EINE ARGININ- UND/ODER TRYPTOPHANVERARMTE MIKROUMGEBUNG RESISTENT SIND

PROCÉDÉ PERMETTANT LA PRODUCTION DE CELLULES IMMUNITAIRES RÉSISTANTES À UN MICROENVIRONNEMENT APPAUVRI EN ARGININE ET/OU EN TRYPTOPHANE

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

11.04.2014 DK 201470209

(43)	Date of publication of application:
	15.02.2017 Bulletin 2017/07

(73)	Proprietor: Cellectis
	75013 Paris (FR)

(72)	Inventors:
	POIROT, Laurent F-75020 Paris (FR) SIMON, Mathieu F-75016 Paris (FR)

(74)	Representative: Zacco Denmark A/S
	Arne Jacobsens Allé 15 2300 Copenhagen S 2300 Copenhagen S (DK)

(56)

References cited: :

WO-A1-2013/176916
WO-A1-2014/191128

WO-A1-2014/184744
US-A1- 2011 058 957

K MORROW ET AL: "Anti-leukemic mechanisms of pegylated arginase I in acute lymphoblastic T-cell leukemia", LEUKEMIA, vol. 27, no. 3, 28 August 2012 (2012-08-28), pages 569-577, XP055137415, ISSN: 0887-6924, DOI: 10.1038/leu.2012.247
DAVID H MUNN ET AL: "GCN2 kinase in T cells mediates proliferative arrest and energy induction in response to indoleamine 2,3-dioxygenase", IMMUNITY, CELL PRESS, US, vol. 22, no. 5, 1 May 2005 (2005-05-01), pages 633-642, XP008129338, ISSN: 1074-7613, DOI: 10.1016/J.IMMUNI.2005.03.013
FALLARINO FRANCESCA ET AL: "The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells", JOURNAL OF IMMUNOLOGY, vol. 176, no. 11, June 2006 (2006-06), pages 6752-6761, XP002729121, ISSN: 0022-1767
NABILA SEDDIKI ET AL: "The microRNA-9/B-lymphocyte-induced maturation protein-1/IL-2 axis is differentially regulated in progressive HIV infection", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 43, no. 2, 1 February 2013 (2013-02-01), pages 510-520, XP055084710, ISSN: 0014-2980, DOI: 10.1002/eji.201242695
SALEHI SOOFIA ET AL: "B Lymphocyte-Induced Maturation Protein-1 Contributes to Intestinal Mucosa Homeostasis by Limiting the Number of IL-17-Producing CD4(+) T Cells", JOURNAL OF IMMUNOLOGY, vol. 189, no. 12, December 2012 (2012-12), pages 5682-5693, XP002729122, ISSN: 0022-1767

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).